Nov. 10 at 12:15 PM
Chardan Capital⬆️
$MNPR's PT to
$100 from
$85, reiterated at a Buy, and said, MNPR (Buy): PT to
$100. Data at AASLD Shows ALXN1840 Improves Copper Balance
$AZN
On 9 November 2025, the company presented new data and analyses from the Phase 2 ALXN1840-WD-204 copper balance study at the American Association for the Study of Liver Diseases (AASLD) meeting. The presented data mirrored that in the 17 September 2025 Letter to the Editor, published in The Journal of Hepatology, in which the authors provide a new analysis of data showing that ALXN1840 rapidly improves copper balance in Wilson disease patients.
